The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
The expert spoke about ongoing trials of novel treatment strategies that may lead to the development of new therapies in this space.
The company’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
This is the first cost-effectiveness analysis of the agent compared with the current standard of care using a constructed population-based control arm.
The dual PI3K/mTOR inhibitor LY3023414 also displayed moderate single-agent activity in this study of patients with heavily pretreated advanced endometrial cancer.
Researchers noted that these findings do not indicate that insurance alone will eliminate racial and ethnic disparities in breast cancer; however, it is one systemic change that may ameliorate consistent disparities.
The device allows plastic surgeons and other supervised specialists to ensure consistently superior, realistic, and customizable results for nipple-areola complex tattooing.
This research indicated that routine HPV testing may be necessary for patients with squamous cell carcinoma.
Researchers have yet to determine the optimal use of the AI system, though assessments in the clinical setting indicated that the technology could enhance screening results, potentially identifying breast cancer earlier than the standard of care.
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor.
This technology identified a practical method for detecting multiple gastrointestinal cancers from a single noninvasive blood test.
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care.
Administering a high dose of gabapentin also increased the percentage of patients who required no opioid during treatment, indicating that patients were possibly gleaning benefits from gabapentin in both treatment arms.
Combined with intensive chemotherapy, the next-generation inhibitor provided excellent results in pediatric patients with Philadelphia chromosome-positive ALL, leading to changes in how this population is treated.